An effective immunotherapy for advanced prostate cancer


Immunotherapy can be effective in some men with advanced prostate cancer.
The drug pembrolizumab caused the tumour to shrink or disappear in 1 in 20 with advanced disease.
Although this 5 % means a small number, some of them gained years of extra life.
Another 19% saw evidence of some sort of improvement.
This trial involved 258 men with advanced prostate cancer who didn't respond to other treatment options.
Those who have mutations in genes involved in repairing DNA in the tumour may benefit more.
Research by the Institute of Cancer Research and the Royal Marsden, published in Journal of Clinical Oncology.

Only 5% saw their tumours shrink, but may be more successful if used earlier

Mentioned in this article:

Academia Institute of Cancer Research

Academic Johann de Bono - Consultant at the Institute of Cancer Research

Journal Journal of Clinical Oncology - Scientific journal of American Society of Clinical Oncology is published 3 times per month

Academic Paul Workman - Chief Executive and President of The Institute of Cancer Research.

Institute Royal Marsden NHS Foundation Trust - Hospital dedicated to cancer diagnosis, treatment, research and education.

Read full article on BBC website
More Cancer information, news and resources